TWM478451U - Antrodia cinnamomea powder capsule structure for inhibiting lymphoma tumor cell proliferation and metastasis - Google Patents

Antrodia cinnamomea powder capsule structure for inhibiting lymphoma tumor cell proliferation and metastasis Download PDF

Info

Publication number
TWM478451U
TWM478451U TW102220972U TW102220972U TWM478451U TW M478451 U TWM478451 U TW M478451U TW 102220972 U TW102220972 U TW 102220972U TW 102220972 U TW102220972 U TW 102220972U TW M478451 U TWM478451 U TW M478451U
Authority
TW
Taiwan
Prior art keywords
capsule
capsule structure
protective layer
core
lymphoma
Prior art date
Application number
TW102220972U
Other languages
Chinese (zh)
Inventor
Chin-Yuan Chan
Original Assignee
Miyuan Biotech Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Miyuan Biotech Co Ltd filed Critical Miyuan Biotech Co Ltd
Priority to TW102220972U priority Critical patent/TWM478451U/en
Publication of TWM478451U publication Critical patent/TWM478451U/en

Links

Landscapes

  • Medicines Containing Plant Substances (AREA)
  • Medicinal Preparation (AREA)

Description

一種抑制淋巴癌腫瘤細胞生長及擴散之牛樟芝粉末膠囊結構A capsule structure of Antrodia camphorata inhibiting the growth and spread of lymphoma tumor cells

本創作係關於一種可包埋粉末之膠囊結構的技術領域。This creation relates to the technical field of a capsule structure that can embed powder.

牛樟芝(Antrodia camphorata),又稱樟芝或牛樟菇等,於分類學上屬於真菌界(Fungi)、擔子菌門(Basidiomycota)、擔子菌亞門(Basidiomycotina)、同擔子菌綱(Homobasidiomycetes)、無褶菌目(Aphyllophorales)、多孔菌科(Polyporaceae)、薄孔菌屬(Antrodia)。牛樟芝生長於海拔450~2000公尺之深山,又名牛樟菇、紅樟、樟菇、樟窟內菇,僅生長於臺灣特有之牛樟樹幹的腐朽心材內壁。牛樟芝目前已知具有多種的活性成分,使得牛樟芝具有護肝、提昇免疫力、抗氧化與抑制腫瘤細胞生長等作用,為臺灣著名且珍貴之藥用真菌,具有「森林中的紅寶石」之美稱。Antrodia camphorata, also known as Antrodia camphorata or Burdock mushroom, belongs to the fungi community (Fungi), Basidiomycota, Basidiomycotina, Homobasidiomycetes, and taxonomy. Aphyllophorales, Polyporaceae, Antrodia. Antrodia camphorata grows in the deep mountains of 450~2000 meters above sea level, also known as burdock mushroom, red peony, oyster mushroom, and oyster mushroom. It grows only on the inner wall of the decaying heartwood of Taiwan's unique burdock trunk. Anthraquinone is known to have a variety of active ingredients, which makes the Antrodia camphorata have the functions of protecting the liver, enhancing immunity, resisting oxidation and inhibiting the growth of tumor cells. It is a famous and precious medicinal fungus in Taiwan and has the reputation of "the ruby in the forest".

牛樟芝子實體為多年生,無柄且為木栓質至木質,具有濃厚的樟樹香氣,形態多變,有板狀、鐘狀、馬蹄狀或塔狀,緊貼於木材表面,菇體表面孔狀,初生時鮮紅色,隨著生長逐變為乳白色、淡紅褐色、淡褐色或淡黃褐色,週邊常呈放射狀,並往四週擴展生長,呈半圓狀或不規則形。The body of Ox sylvestris is perennial, sessile and cork-to-wood. It has a strong aroma of eucalyptus and has a variety of shapes. It has a plate shape, a bell shape, a horseshoe shape or a tower shape. It is close to the surface of the wood and has a pore shape on the surface of the mushroom. It is bright red at the beginning of life, and becomes milky white, reddish brown, light brown or yellowish brown as the growth progresses. The periphery is often radial and spreads to the periphery, showing a semicircular or irregular shape.

植物化學研究顯示,牛樟芝子實體包含多醣(30-50%)、三萜類(30%)、類固醇類、超氧化物歧化酶和氨基酸類。在台灣民俗醫學療法上,牛樟芝子實體被認為具有某些醫藥功效,將該子實體細磨成乾燥粉末或以熬煮方式口服,為民間流傳具療效的食藥菇類,具有解毒、抗發炎、抗腫瘤、抑制血管增生及治療肝臟疾病等活性。Phytochemical studies have shown that the body complex of Antrodia camphorata contains polysaccharides (30-50%), triterpenoids (30%), steroids, superoxide dismutase and amino acids. In Taiwan's folk medicine therapy, the body of A. sylvestris is considered to have certain medical effects. The fruiting body is finely ground into a dry powder or taken orally in a boiled way. It is a food-borne mushroom with a therapeutic effect. It has detoxification and anti-inflammatory. , anti-tumor, inhibition of vascular proliferation and treatment of liver disease and other activities.

惡性淋巴瘤俗稱淋巴癌,其中包括了兩種疾病,即非何杰金氏淋巴瘤與何杰金氏症。兩者的差別在於病理型態學的不同以及臨床表現的差異。西方人何杰金氏症較普通,預後比較好,而東方人則非何杰金氏淋巴瘤比較多。目前看來全世界的惡性淋巴瘤有逐年上升的趨勢,罹病率仍逐年增加。Malignant lymphoma, commonly known as lymphoma, includes two diseases, non-Hodgkin's lymphoma and Hodgkin's disease. The difference between the two is the difference in pathological morphology and the difference in clinical manifestations. Westerner Hodgkin's disease is more common, the prognosis is better, while the Orientals are more than Hodgkin's lymphoma. At present, it seems that the world's malignant lymphoma has a trend of increasing year by year, and the rickets rate is increasing year by year.

惡性淋巴瘤的成因有許多假說,大部份學者認為除了體質、化學物質、病毒感染(EB病毒)之外,病人本身的免疫功能缺損佔很重要的角色,如腎臟移植者、AIDS愛滋病毒,或特殊病毒感染者,其罹病率為正常人的數十倍。家族及遺傳的傾向則很少見。There are many hypotheses about the causes of malignant lymphoma. Most scholars believe that in addition to physical, chemical, and viral infections (EBV), the patient's own immune function defects play an important role, such as kidney transplanters, AIDS HIV. Or a special virus infected person, the rate of rickets is dozens of times that of normal people. Family and genetic tendencies are rare.

發生淋巴癌之可能原因包含免疫系統的缺失、病毒感染、放射線或藥物的使用以及遺傳等。研究指出淋巴癌於各個年齡層之發病率很平均,且男女之發病人數比例約相等,淋巴癌最常以淋巴腺腫大為早期症狀,尤其好發於頸部、腋下或腹股溝等部位的淋巴節,且常為無痛性成串的淋巴節腫大,有些患者會出現全身性症狀,如發燒、夜間盜汗、體重減輕、長期倦怠感或無力感、皮膚癢發疹等徵候;此外,有約三分之一淋巴癌之初發病灶不在淋巴腺,而發生於內臟器官,如胃、大小腸、肺之縱膈腔等,其症狀包含胃痛、胃出血、腸阻塞、或肺部呼吸困難等。Possible causes of lymphoma include loss of the immune system, viral infection, use of radiation or drugs, and heredity. Studies have shown that the incidence of lymphoma in all age groups is very average, and the proportion of men and women is about equal. Lymphoma is most often characterized by lymphadenopathy as an early symptom, especially in the lymph nodes of the neck, armpits or groin. Sections, and often painless clusters of lymph nodes, some patients may have systemic symptoms such as fever, night sweats, weight loss, long-term burnout or weakness, skin itching and rash, etc. The first stage of the lymphoma is not in the lymph glands, but in the internal organs, such as the stomach, the large intestine, the mediastinum of the lungs, etc., and its symptoms include stomach pain, stomach bleeding, intestinal obstruction, or lung dyspnea. .

淋巴癌的病人若不接受治療,一般而言平均活存不超過一到二年。但接受適當的放射線治療或化學治療者,達成完全緩解的機率約佔六到七成,這群病人中有百分之四十的病人可能會復發。治療兩年後才復發者,預後比較好,他們仍然對第二次的化學治療有良好的反應。不論有沒有復發過,只要適當地接受治療者,七年以上的存活率約佔所有淋巴癌的四成左右,這個成績在癌病中是相當好的成績。Patients with lymphoma who do not receive treatment generally live on average for no more than one to two years. However, those who receive appropriate radiation therapy or chemotherapy will have a 60% to 70% chance of achieving complete remission, and 40% of these patients may relapse. Those who relapsed after two years of treatment have a better prognosis and they still have a good response to the second chemotherapy. Regardless of whether there has been recurrence, as long as the appropriate treatment, the survival rate of more than seven years accounts for about 40% of all lymphoma, and this result is quite good in cancer.

由目前諸多之實驗可得知牛樟芝子實體具有抗癌功效,且其所含成分亦陸續被分析出。因此,若能提供該等患者一更佳之治療或預防淋巴癌之方法,是一迫切亟需解決之課題。It is known from many experiments that the body of A. angustifolia has anti-cancer effect, and its components are also analyzed. Therefore, providing a better treatment or prevention of lymphoma in these patients is an urgent problem to be solved.

由此,本案創作人鑑於上述衍生之缺失,乃亟思加以改良創新,除了研發一牛樟芝粉末,其中之活性成分具有抑制淋巴癌腫瘤細胞生長及擴散之效用;此外,搭配本創作之膠囊結構,可供使用者易於攝取足夠之牛樟芝粉末,並藉此治療、或預防淋巴癌。是故,提出本件『一種抑制淋巴癌腫瘤細胞生長及擴散之牛樟芝粉末膠囊結構』。Therefore, in view of the above-mentioned lack of the above-mentioned derivatives, the creators of this case have improved and innovated, in addition to the development of a burdock powder, the active ingredient of which has the effect of inhibiting the growth and spread of lymphoma tumor cells; in addition, with the capsule structure of the creation, It is easy for the user to ingest enough of the Antrodia camphorata powder to treat or prevent lymphoma. Therefore, this article "a structure of a capsule of Astragalus membranaceus that inhibits the growth and spread of lymphoma cells".

本創作之目的即在於提供一種用以抑制淋巴癌腫瘤細胞生長的牛樟芝粉末膠囊結構。The purpose of the present invention is to provide a structure of an Antrodia camphorata powder capsule for inhibiting the growth of lymphoma tumor cells.

本創作之次一目的在於提供一種膠囊結構,以使其中之牛樟芝粉末之活性成分得以於服用者體內發揮其抑制淋巴癌腫瘤細胞生長及擴散之效用。A second object of the present invention is to provide a capsule structure in which the active ingredient of the Antrodia camphorata powder is exerted in a user's body to inhibit the growth and spread of lymphoma tumor cells.

可達成上述創作目的之一種抑制淋巴癌腫瘤細胞生長及擴 散之牛樟芝粉末膠囊結構,包括:一囊殼、一保護層、及一核心;該核心係被該保護層所披覆,該保護層再以一囊殼包覆之。One of the above-mentioned creative purposes can inhibit the growth and expansion of lymphoma tumor cells The powdered capsule structure of A. sinensis comprises: a capsule shell, a protective layer, and a core; the core layer is covered by the protective layer, and the protective layer is coated with a capsule.

本創作所提供之牛樟芝粉末膠囊結構,除了可供內含之牛樟芝粉末(及其活性成分)得以被長時間保存外;此外,其核心所含之牛樟芝粉末(及其活性成分)亦可抑制淋巴癌細胞生長及擴散。本創作提供之膠囊結構可易於使使用者服用,因此,除可用於日常保健外,亦可搭配其他療程一併使用之。The structure of the Antrodia camphorata powder capsule provided by the present invention can be preserved for a long time in addition to the contained Antrodia camphorata powder (and its active ingredient); in addition, the core of the Antrodia camphorata powder (and its active ingredient) can also inhibit lymphatics. Cancer cells grow and spread. The capsule structure provided by this creation can be easily taken by the user, so that it can be used in combination with other treatments in addition to daily health care.

1‧‧‧膠囊結構1‧‧‧Capsule structure

11‧‧‧囊殼11‧‧‧ capsule

12‧‧‧保護層12‧‧‧Protective layer

13‧‧‧核心13‧‧‧ core

圖一為一種抑制淋巴癌腫瘤細胞生長及擴散之牛樟芝粉末膠囊結構的剖面圖。Figure 1 is a cross-sectional view showing the structure of an Antrodia camphorata powder capsule which inhibits the growth and spread of lymphoma tumor cells.

本創作係提供一種抑制淋巴癌腫瘤細胞生長及擴散之牛樟芝粉末膠囊結構,根據本創作詳細說明之,並請參閱第一圖說明。The present invention provides a structure of an Antrodia camphorata powder capsule which inhibits the growth and spread of lymphoma tumor cells, and is described in detail according to the present creation, and is referred to the first figure.

本創作之抑制淋巴癌腫瘤細胞生長及擴散之牛樟芝粉末膠囊結構1,由外至內依序包括:一囊殼11、一保護層12、及一核心13;該核心13係被該保護層12所披覆,除了可用以阻隔外界環境與該核心13之間的氧化作用外,亦可用以保護核心13中之牛樟芝活性成分不受胃酸等因素所破壞。另,該保護層12再以一囊殼11包覆,以保護核心13及保護層12免於受物理性因子(如:重壓、尖刺等)之破壞。The present invention comprises a structure 1 for inhibiting the growth and spread of lymphoma tumor cells, which comprises, in order from the outside to the inside, a capsule 11, a protective layer 12, and a core 13; the core 13 is protected by the protective layer 12 The coating, in addition to blocking the oxidation between the external environment and the core 13, can also be used to protect the active constituents of the Antrodia camphorata in the core 13 from being damaged by factors such as gastric acid. In addition, the protective layer 12 is further covered by a capsule 11 to protect the core 13 and the protective layer 12 from physical factors such as heavy pressure, spikes, and the like.

其中該囊殼11所用之成分包含但不限於:明膠(吉利丁 (Gelatin))、甲基纖維素(Methyl cellulose)、羥丙基甲基纖維素(Hydroxymethyl propyl cellulose)、羥丙基纖維素(Hydroxymethyl propyl cellulose)、聚乙烯醇(Polyvinyl alcohol)、聚乙烯吡咯酮(Polyvinyl pyrrolidone)、鄰苯二甲酸醋酸纖維素(Cellulose acetate phthalate)、鄰苯二甲酸羥丙基纖維素(Hydroxypropyl methylcellulose phthalate)或其它適用於本創作的材料;其中該明膠可包含動物性明膠(由魚皮、豬皮等動物性來源所製成)及植物性明膠(如:羥丙基甲基纖維素(HPMC))。The components used in the capsule 11 include, but are not limited to, gelatin (gelatin) (Gelatin)), Methyl cellulose, Hydroxymethyl propyl cellulose, Hydroxymethyl propyl cellulose, Polyvinyl alcohol, Polyvinylpyrrolidone (Polyvinyl pyrrolidone), Cellulose acetate phthalate, Hydroxypropyl methyl phthalate or other materials suitable for the present invention; wherein the gelatin may comprise animal gelatin ( Made from animal sources such as fish skin and pig skin) and vegetable gelatin (eg hydroxypropyl methylcellulose (HPMC)).

其中該保護層12之可包含但不限於:賦形劑、崩解劑、腸溶衣、黏合劑、稀釋劑、包覆劑、潤脹劑、潤滑劑、調味劑、甜味劑、增溶劑、或其之任意組合。The protective layer 12 may include, but is not limited to, an excipient, a disintegrant, an enteric coating, a binder, a diluent, a coating agent, a swelling agent, a lubricant, a flavoring agent, a sweetener, a solubilizing agent. Or any combination thereof.

其中,如賦形劑可為糖類,包括乳糖、蔗糖、甘露醇、山梨醇;纖維素製備物像是,例如,玉米澱粉、小麥澱粉、稻米澱粉、馬鈴薯澱粉、明膠、黃蓍膠等或其他適用本創作之材料;其可用以增加口感、支撐整體之結構、及保護核心13。Wherein, the excipient may be a sugar, including lactose, sucrose, mannitol, sorbitol; the cellulose preparation is, for example, corn starch, wheat starch, rice starch, potato starch, gelatin, tragacanth, etc. or other Materials suitable for this creation; they can be used to increase the mouthfeel, support the overall structure, and protect the core 13.

其中該核心13中包含牛樟芝粉末(活性物質),其可用以抑制淋巴癌腫瘤細胞生長及擴散。該牛樟芝粉末可從牛樟芝子實體中製成。The core 13 contains an Antrodia camphorata powder (active substance) which can be used to inhibit the growth and spread of lymphoma tumor cells. The Antrodia camphorata powder can be made from the fruit body of Antrodia camphorata.

上述膠囊結構1亦可視需要適宜地添加一或多種以上該領域通常會使用的保存劑、著色劑、香料及風味劑或其它適用於本創作的添加物,以使其賦形、保存、上色、增添風味。The above-mentioned capsule structure 1 may also be suitably added with one or more kinds of preservatives, colorants, flavors and flavors or other additives suitable for the present invention which are commonly used in the field, so as to shape, preserve and color. Add flavor.

上述粉末膠囊結構可藉由製備於膠囊內以供口服外,亦可直接服用、或藉由其他適用本創作之形式服用。The above powder capsule structure can be prepared by taking it in a capsule for oral administration, or by taking it directly or by other forms suitable for the present invention.

上列詳細說明係針對本創作之一可行實施方式之具體說 明,惟該實施例並非用以限制本創作之專利範圍,凡未脫離本創作技藝精神所為之等效實施或變更,均應包含於本案之專利範圍中。The detailed description above is specific to one of the possible implementations of this creation. It is to be understood that the examples are not intended to limit the scope of the patents of the present invention, and that equivalents or modifications may be included in the scope of the patent.

綜上所述,本案所揭露之技術特徵已充分符合新穎性、進步性及產業利用性之法定專利要件,爰依法提出申請,懇請 貴局核准本件新型專利申請案,以勵發明,至感德便。In summary, the technical features disclosed in this case have fully met the statutory patent requirements for novelty, advancement and industrial applicability. If you apply in accordance with the law, you are requested to approve the new patent application for your invention. Will.

1‧‧‧膠囊結構1‧‧‧Capsule structure

11‧‧‧囊殼11‧‧‧ capsule

12‧‧‧保護層12‧‧‧Protective layer

13‧‧‧核心13‧‧‧ core

Claims (5)

一種抑制淋巴癌腫瘤細胞生長及擴散之牛樟芝粉末膠囊結構,由外至內依序包含:一囊殼、一保護層、及一核心;該核心係被該保護層所披覆,該保護層再以一囊殼包覆之。 An anathopin powder capsule structure for inhibiting the growth and spread of lymphoma tumor cells, comprising: a capsule shell, a protective layer, and a core from the outside to the inside; the core layer is covered by the protective layer, and the protective layer is further Covered with a capsule. 如申請專利範圍第1項所述之膠囊結構,其中該囊殼之成分包含明膠、甲基纖維素、羥丙基甲基纖維素、羥丙基纖維素、聚乙烯醇、聚乙烯吡咯酮、鄰苯二甲酸醋酸纖維素、鄰苯二甲酸羥丙基纖維素。 The capsule structure according to claim 1, wherein the composition of the capsule comprises gelatin, methylcellulose, hydroxypropylmethylcellulose, hydroxypropylcellulose, polyvinyl alcohol, polyvinylpyrrolidone, Cellulose acetate phthalate, hydroxypropyl cellulose phthalate. 如申請專利範圍第1項所述之膠囊結構,其中該保護層之成分包含賦形劑㊣、崩解劑、腸溶衣、黏合劑、稀釋劑、包覆劑、潤脹劑、潤滑劑、調味劑、甜味劑、增溶劑。 The capsule structure according to claim 1, wherein the component of the protective layer comprises an excipient, a disintegrant, an enteric coating, a binder, a diluent, a coating agent, a swelling agent, a lubricant, Flavoring agents, sweeteners, solubilizers. 如申請專利範圍第3項所述之膠囊結構,其中該賦形劑之成分包含乳糖、蔗糖、甘露醇、山梨醇、玉米澱粉、小麥澱粉、稻米澱粉、馬鈴薯澱粉、明膠、黃蓍膠。 The capsule structure of claim 3, wherein the component of the excipient comprises lactose, sucrose, mannitol, sorbitol, corn starch, wheat starch, rice starch, potato starch, gelatin, tragacanth. 如申請專利範圍第1項所述之膠囊結構,其中該核心包含從牛樟芝子實體中製成之牛樟芝粉末。 The capsule structure of claim 1, wherein the core comprises anthraquinone powder prepared from a body of A. nigra.
TW102220972U 2013-11-08 2013-11-08 Antrodia cinnamomea powder capsule structure for inhibiting lymphoma tumor cell proliferation and metastasis TWM478451U (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
TW102220972U TWM478451U (en) 2013-11-08 2013-11-08 Antrodia cinnamomea powder capsule structure for inhibiting lymphoma tumor cell proliferation and metastasis

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
TW102220972U TWM478451U (en) 2013-11-08 2013-11-08 Antrodia cinnamomea powder capsule structure for inhibiting lymphoma tumor cell proliferation and metastasis

Publications (1)

Publication Number Publication Date
TWM478451U true TWM478451U (en) 2014-05-21

Family

ID=51295825

Family Applications (1)

Application Number Title Priority Date Filing Date
TW102220972U TWM478451U (en) 2013-11-08 2013-11-08 Antrodia cinnamomea powder capsule structure for inhibiting lymphoma tumor cell proliferation and metastasis

Country Status (1)

Country Link
TW (1) TWM478451U (en)

Similar Documents

Publication Publication Date Title
Burk Puffball usages among North American indians
TW201345538A (en) Use of antrodia camphorata for treating skin conditions
JP6369931B2 (en) Anti-obesity agent
TWM478451U (en) Antrodia cinnamomea powder capsule structure for inhibiting lymphoma tumor cell proliferation and metastasis
TWM478454U (en) Antrodia cinnamomea powder capsule structure for inhibiting gastric cancer tumor cell proliferation and metastasis
TWM478484U (en) Antrodia camphorata powder capsule structure for suppressing growth and metastasis of tumor cells of liver cancer
TWM481014U (en) Antrodia cinnamomea powder capsule structure for the treatment of tumor cells
Jones Reishi mushroom: Ancient medicine in modern times
TWM478489U (en) Antrodia cinnamomea powder capsule structure for suppressing hepatitis B virus
TWM478453U (en) Antrodia cinnamomea powder capsule structure for inhibiting esophageal cancer tumor cell proliferation and metastasis
TWM478455U (en) Antrodia cinnamomea powder capsule structure for inhibiting lung cancer tumor cell proliferation and metastasis
TWM478494U (en) Antrodia camphorate powder capsule structure for suppressing growth and propagation of tumor cells of pancreatic cancer
TWM478493U (en) Antrodia camphorata powder capsule structure for suppressing growth and metastasis of tumor cells of oral cancer
TWM478492U (en) Antrodia cinnamomea powder capsule structure for suppressing growth and proliferation of tumor cells of skin cancer
TWM478488U (en) Antrodia camphorate powder capsule structure for suppressing growth and propagation of tumor cells of nasopharyngeal cancer
TWM478490U (en) Antrodia camphorata powder capsule structure for suppressing growth and metastasis of tumor cells of brain cancer
TWM478483U (en) Antrodia cinnamomea powder capsule structure for suppressing growth and proliferation of tumor cells of colorectal cancer
TWM478487U (en) Antrodia camphorata powder capsule structure for liver protection and enhancement of immunity
TWM478471U (en) Embedding structure of Antrodia cinnamomea particle for improve gastrointestinal disease
TWM485048U (en) Antrodia cinnamomea powder capsule structure having anticancer and antioxidation functions
TWM522731U (en) Composite tablet structure with stout camphor carrier
CN110237201A (en) A kind of drug for treating chronic pulmonary aspergilosis
TWM481015U (en) Antrodia cinnamomea powder capsule structure for inhibiting cancer cell proliferation
TWM478452U (en) Antrodia cinnamomea powder capsule structure for inhibiting bone cancer tumor cell proliferation and metastasis
TWM478447U (en) Antrodia cinnamomea powder capsule structure having assisting anticancer drug

Legal Events

Date Code Title Description
MM4K Annulment or lapse of a utility model due to non-payment of fees